Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
95
resultados
Última actualización
30/07/2025 [07:14:00]
Resultados 25 a 50 de 95
Resumen de: US2025195631A1
To make an immunotherapy that is effective for a larger group of cancer patients, Salmonella have been genetically engineered to deliver proteins from prior vaccines into the cytoplasm of tumor cells.
Resumen de: AU2023323947A1
The invention is directed to immunogenic compositions and method of treatment comprising a peptide or nucleic acid that encodes the peptide that induces an immune response in a mammal that is protective against infection by one or more pathogens. The peptide sequence contains multiple epitopes, wherein at least one epitope is a composite epitope which is a combination of two or more conserved epitopes of the pathogen wherein the amino acid sequence of the composite is not an amino acid sequence of the pathogen. In addition, the invention is directed to vaccines comprising the peptide or nucleic acid that encodes the peptide for treating and preventing an infection in mammals such as animals and humans.
Resumen de: US2025025552A1
The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
Resumen de: WO2025122955A1
Provided herein are methods and compositions for treating cancer. One composition includes an engineered bacterial cell comprising: a) a lysis gene or lysis cassette operably linked to an intracellularly induced Salmonella promoter; b) one or more of the bacterial cell genes selected from the group consisting of recA, recB, recF, sbcB, sbcCD, red, sseJ or any combination thereof are knocked out; and c) a nucleic acid sequence coding for an oncolytic virus genome.
Resumen de: WO2024155027A1
The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer efficacy, and thus can be used as a therapeutic agent for cancer together with or independently of existing anti-cancer drugs.
Resumen de: CN120118166A
本发明通过筛选、实验验证获得一段能够代表沙门氏菌作为抗原的特异性蛋白片段，以这一段特异性蛋白片段作为抗原免疫小鼠，利用细胞融合技术得到可以稳定分泌单克隆抗体的杂交瘤细胞，最终制备了效价高、特异性好的抗沙门氏菌单克隆抗体。同样以该特异性蛋白片段免疫兔子，获得了抗沙门氏菌多克隆抗体。基于鼠单克隆抗体和兔多克隆抗体，建立沙门氏菌胶体金免疫层析检测方法，该检测方法特异性良好，为食品中沙门氏菌的检测提供了快速、简便的检测手段。
Resumen de: US2025177508A1
Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.
Resumen de: US2025177534A1
This invention describes method for inactivation of microorganisms in thermostable dry formulations at ambient temperatures (AT) using UV light irradiation. According to this method microorganisms are inactivated at ambient temperatures (AT) in dry formulations where the amount of free radicals formed is relatively small and damage of nucleic acids is the main cause for the microorganism's death. The method will allow production of thermostable inactivated vaccines from wild type and live attenuated microorganisms, thermostable inactivated microbiome products, and thermostable sterilized none-live blood components, therapeutic proteins, antibodies and other fragile biopharmaceuticals.
Resumen de: AU2023312737A1
Provided herein are vaccine composition comprising a
Resumen de: CN120081916A
本发明公开了一种鼠伤寒沙门菌特异性抗原片段及其在检测鼠伤寒沙门菌抗体中的应用。所述鼠伤寒沙门菌特异性抗原片段的氨基酸序列如SEQ ID NO.1所示。本发明首次公开了以鼠伤寒沙门菌特异性抗原片段作为间接ELISA的包被抗原，建立了鼠伤寒沙门菌间接ELISA抗体检测方法，鼠伤寒沙门菌特异性抗原片段含有鼠伤寒沙门菌FliC蛋白的优势B细胞表位，能够特异性识别诱导产生的鼠伤寒沙门菌FliC蛋白抗体，在提高抗原抗体特异性结合方面有显著性的增效作用。本发明能够用于鼠伤寒沙门菌抗体的检测，为鼠伤寒沙门菌的流行病学调查以及沙门菌的防控提供了有力的技术支持。
Resumen de: CN120053424A
The invention belongs to the technical field of anti-infection drugs, and particularly relates to medical application of apigenin in preparation of a salmonella flagellum inhibitor. A migration inhibition test (0.3% agar), minimum inhibitory concentration (MIC) determination, a Caco-2 cell adhesion test and a molecular docking test prove that the apigenin can specifically inhibit salmonella flagellum-mediated migration ability (inhibition rate gt; 49%) and host cell adhesion capability (reduced by more than or equal to 58%), and does not affect bacterial growth (pgt; 0.05), the apigenin can be used for targeting flagellin FljB, FliC, FlgN, FlgA and FlgG (binding energy per lt; -5kcal/mol) can block flagellar movement, and has an application prospect in prevention and control of livestock salmonella related diseases.
Resumen de: CN120052369A
The invention discloses a preparation method of a fresh fruit and vegetable surface cleaning disinfectant and application of the fresh fruit and vegetable surface cleaning disinfectant in fruit and vegetable cleaning.The preparation method comprises the steps that firstly, the antibacterial effect of citric acid, tartaric acid and sodium hypochlorite is evaluated, the synergistic antibacterial effect of different compounding modes is optimized, and meanwhile the optimal compounding formula is screened out; and the antibacterial activity is verified by using a time-sterilization curve. The compound disinfectant has an obvious inhibition effect on typical food-borne pathogenic bacteria such as salmonella typhimurium and escherichia coli O157: H7, and meanwhile, in fruit and vegetable cleaning application, the effectiveness of the synergistic antibacterial effect of the method is evaluated under a cherry tomato and lettuce system; and the molecular mechanism of sterilization is explored from the aspects of cell membrane morphology and property change at the cellular level, and the synergistic effect mechanism of citric acid and sodium hypochlorite is discussed. The method can be applied to fresh fruit and vegetable surface cleaning and disinfection, and an important theoretical basis is provided for guaranteeing the safety of fresh fruit and vegetable microorganisms.
Resumen de: CN120060507A
The invention discloses a multi-pathogen visual detection method based on top-speed PCR (Polymerase Chain Reaction), and belongs to the technical field of molecular biological detection. The invention designs specific primers and molecular beacons of salmonella Sa, vibrio parahaemolyticus VP and infectious subcutaneous and hematopoietic necrosis virus IHHNV for multiple PCR (Polymerase Chain Reaction), and three pathogens can be simultaneously amplified in a PCR system. In addition, the molecular beacon and the target are combined to expose the fluorophore, and the three pathogens can be distinguished without opening a cover by means of a self-made visual device. The multiple visual PCR detection method provided by the invention has the advantages of strong specificity, high sensitivity, short detection time, direct observation and the like, can realize simultaneous detection of multiple pathogens in a single sample, saves the cost, has higher economic value, and is suitable for on-site instant detection.
Resumen de: CN120064644A
The invention discloses a high-specificity pullorum disease salmonella gallinarum plate agglutination antigen preparation process, which comprises the following steps: respectively resuscitating pullorum disease salmonella C79-1 and C79-7 strains to prepare seed solutions, inoculating a suitable culture medium, carrying out fermentation culture according to a specific process, carrying out centrifugal collection on thalli after inactivation, and carrying out freeze drying to obtain the high-specificity pullorum disease salmonella gallinarum plate agglutination antigen. The preparation method comprises the following steps: carrying out high pressure at 121 DEG C for 2 hours, washing for multiple times, removing protein antigen components which are easily subjected to cross reaction with escherichia coli or enterobacteriaceae bacteria which are commonly used in other environments, adjusting the C79-1 strain and the C79-7 strain to proper bacterium concentration, adding Tween-20, crystal violet and glycerol, and fully homogenizing to obtain the salmonella typhimurium plate agglutination antigen for pullorum disease. The antigen has higher specificity, and is more accurate when being used for purifying and detecting the pullorum disease; according to the fermentation process, the bacterial yield is 4 times of that of common fermentation and 2 times of that of solid culture, ethanol precipitation is not needed, and the production cost is lower; tween-20 is added, so that the surfa
Resumen de: NZ752690A
An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.
Resumen de: CN120060007A
The invention relates to the technical field of microorganisms, in particular to clostridium butyricum CB24011205 capable of inhibiting growth and colonization of vibrio cholerae and application of the clostridium butyricum CB24011205. According to the present invention, the clostridium butyricum CB24011205 strain is separated from the intestinal tract content of the marine white shrimp, and the preservation number of the clostridium butyricum CB24011205 strain is CGMCC No. 33030; the strain has the capability of efficiently inhibiting vibrio cholerae, can be compounded with daidzein to prepare a microecological preparation, not only has remarkable advantages in colonization and growth of vibrio cholerae, but also can provide certain protection for other pathogenic bacteria (such as escherichia coli and salmonella), can be used for enhancing intestinal immunity and repairing functions, and can be used for preparing the microecological preparation. Good application prospects are realized.
Resumen de: CN120058920A
The invention discloses an anti-S11 type riemerella anatipestifer monoclonal antibody as well as a blocking ELISA antibody detection kit and application thereof, and belongs to the technical field of poultry immunology. The monoclonal antibody provided by the invention comprises a heavy chain and a light chain, the heavy chain comprises VHCDR1, VHCDR2 and VHCDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and the light chain comprises VLCDR1 of which the amino acid sequence is as shown in SEQ ID NO: 4, VLCDR2 of which the amino acid sequence is LVS and VLCDR3 of which the amino acid sequence is as shown in SEQ ID NO: 5; the blocking ELISA antibody detection kit prepared from the monoclonal antibody can specifically detect the level of a riemerella anatipestifer serotype 11 (S11 type) antibody in a sample, has no cross reactivity with riemerella anatipestifer S1 type, riemerella anatipestifer S2 type, riemerella anatipestifer S5 type, riemerella anatipestifer S6 type and riemerella anatipestifer S14 type, avian pathogenic escherichia coli, avian pasteurella multocida and salmonella, and is high in sensitivity and specificity.
Resumen de: CN120060515A
The invention discloses an RPA primer group and a kit for rapidly detecting salmonella pullorum based on RPA-CRISPR/Cas12a, and belongs to the technical field of salmonella pullorum visual rapid detection. A specific target gene ipaj in a salmonella pullorum genome is taken as a target spot, an RPA primer pair and a specific crRNA sequence are designed and optimized, the salmonella pullorum is detected by combining an RPA isothermal amplification method and a CRISPR/Cas12a detection method, a detection result can be interpreted by naked eyes under blue light, and the detection result is accurate. The kit has the characteristics of high sensitivity, strong specificity, accurate result, short time consumption, simplicity and convenience in operation and high practicability, and is suitable for rapid screening or detection of the pullorum disease on site.
Resumen de: CN120060163A
The invention discloses an Escherichia coli bacteriophage PEC-36 with cross-species host characteristics and application of the Escherichia coli bacteriophage PEC-36, and belongs to the technical field of biology. The Escherichia coli bacteriophage PEC-36 is separated from sewage of a pig factory, can simultaneously split O8: H7, O21: H34, O23: H16, O25: H4, O81: H27 and H25 serotype strains of Escherichia coli and fowl typhoid, London, swine cholera and other serotype strains of salmonella, and has a cross-species splitting characteristic. Experiments prove that the bacteriophage has the advantages of high titer, high stability, high safety and the like, and can remarkably inhibit the growth of escherichia coli and salmonella, so that a technical support is provided for research and development of bacteriophage preparations for treating infection related to escherichia coli and salmonella; the invention provides a safe and efficient antibiotic alternative scheme for treating human and animal Escherichia coli and salmonella related infection, and has a good application prospect.
Resumen de: CN120053379A
Construction and application of an intratumoral self-proliferation enhanced oncolytic microbial delivery system belong to the technical field of pharmaceutical preparations, a hydrogen sulfide donor is endowed with a membrane-insertable regional structure through a synthetic reaction, then a lipid membrane containing the membrane-insertable hydrogen sulfide donor is coated with bacteria through a self-assembly effect, and the membrane-insertable hydrogen sulfide donor is obtained. An oncolytic microbial delivery system with enhanced intratumoral self-proliferation is prepared. After the delivery system is intravenously injected, the delivery system is enriched in a tumor in a targeted manner, hydrogen sulfide released by a donor can be converted into tetrathionate in a tumor inflammation microenvironment, tetrathionate respiration belongs to specific respiration of salmonella, and the specific respiration belongs to specific respiration of salmonella. The proliferation of a salmonella tumor part is specifically promoted through two respiratory chains of aerobic respiration and tetrasulfate respiration, so that the pyroptosis of tumor cells is enhanced, and the anti-tumor purpose is achieved. The invention provides a brand new theory and an advanced solution for cancer treatment, also provides a promising strategy and exploration thought for clinical application of attenuated salmonella, and has important scientific research value.
Resumen de: CN120060164A
The invention relates to the technical field of microorganisms, in particular to a salmonella manhattan phage and application thereof. The phage is named as vB Sal M467 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.46195, and the preservation date is September 29, 2024. The bacteriophage provided by the invention is separated from sewage of a farm and belongs to a tailed virus, and genomics shows that the bacteriophage belongs to a Kayfunavius genus, a non-virulence gene and a drug-resistant gene, and has safety. The biological characteristic result of the bacteriophage shows that at least eight salmonella serotypes can be split, the bacteriophage has good stability to temperature (-20 DEG C to 60 DEG C) and acid-base property (pH = 3-12), the outbreak amount is 158.83 PFU/cell, and the bacteriophage can be massively proliferated in a short time. The bacteriophage can be used for preventing and controlling salmonella in food such as lettuce and milk.
Resumen de: CN120060052A
The invention discloses a strain of enterococcus faecium HKS023 and application of the enterococcus faecium HKS023. The enterococcus faecium HKS023 is preserved in China General Microbiological Culture Collection Center on February 14, 2023, and the preservation number of the enterococcus faecium HKS023 is CGMCC No.26552. The enterococcus faecium HKS023 is named as enterococcus faecium HKS023. According to the invention, a new strain of enterococcus faecium HKS023 is screened from fresh feces of healthy weaned piglets, corn flour is taken as a raw material, L-lactic acid is produced through fermentation, the acid yield is high, and the enterococcus faecium HKS023 has a very strong inhibition effect on the growth of salmonella and can inhibit the growth of escherichia coli and staphylococcus aureus to a certain extent. The enterococcus faecium HKS023 microbial feed additive is produced by effectively combining and fermenting common raw materials including calcium carbonate, beef extract, yeast extract, peptone, glucose, sodium acetate, dipotassium phosphate, magnesium sulfate, manganese sulfate and the like, the growth performance of livestock and poultry can be effectively improved, the diarrhea rate is reduced, the immunity of the livestock and poultry is improved, and the economic and social benefits are huge.
Resumen de: US2025170230A1
The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
Resumen de: US2025169515A1
A continuous feed, shell egg pasteurization system and method uses sprayed heated water. The unpasteurized shell eggs are conveyed and rotated through a horizontal tunnel. An overlapping pattern of heated water is sprayed downward onto the rotating shells eggs. Verified testing shows that the shell eggs achieve a statistical 5 log reduction of Salmonella enteritidis that may have been present in the yolk in the respective unpasteurized shell egg, while at the same time are not overcooked and have little to no whitening of the albumen.
Nº publicación: CN120051271A 27/05/2025
Solicitante:
SINYANG BIOMEDICAL CO LTD
\u6B23\u626C\u751F\u533B\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: CN120051271A
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) a micelle having a shell formed from one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or a combination thereof and having an agent encapsulated within the shell. The methods of the present invention can effectively treat viral infections, such as, for example; severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus, HIV, hepatitis B virus, MERS-CoV, influenza virus, dengue fever virus, respiratory syncytial virus, hepatitis C virus, monkey pox virus, human papilloma virus, methicillin-resistant staphylococcus aureus, pseudomonas, tuberculosis, bacillus anthracis, tetanus, streptococcus pneumoniae, meningococcus, escherichia coli, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, , Legionella genus, Neisseria gonorrhoeae, Neisseria meningitidis, and Salmonella genus.
BOPI
Sede Electrónica
